Clinical Trial: A Study to Evaluate the Safety, Reactogenicity, and Immune Response of the GSK Vaccines Institute for Global Health (GVGH) Quadrivalent Pan-Salmonella Vaccine With and Without Alum in Healthy Young Adults

U.S., June 24 -- ClinicalTrials.gov registry received information related to the study (NCT07663032) titled 'A Study to Evaluate the Safety, Reactogenicity, and Immune Response of the GSK Vaccines Institute for Global Health (GVGH) Quadrivalent Pan-Salmonella Vaccine With and Without Alum in Healthy Young Adults' on June 17.

Brief Summary: The current clinical study will evaluate the GVGH Quadrivalent Pan-Salmonella vaccine for the first time in healthy adults in Africa. The purpose of the current Phase 1 study is to evaluate the safety, reactogenicity, and the immune response induced by the Pan-Salmonella vaccine.

Study Start Date: June 24

Study Type: INTERVENTIONAL

Condition: Salmonella Infections

Intervention: BIOLOGICAL: Pan-Salm...